Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
biote Community
NasdaqGM:BTMD Community
3
Narratives
written by author
0
Comments
on narratives written by author
12
Fair Values set
on narratives written by author
Create a narrative
biote
Popular
Undervalued
Overvalued
Community Investing Ideas
biote
AN
AnalystLowTarget
Consensus Narrative from 5 Analysts
Competitive Regulatory Risks Will Hamper Healthcare Yet Value Will Rebound
Key Takeaways Heavy reliance on hormone therapies and regulatory scrutiny could threaten long-term revenue stability and market share despite growth in supplements and provider network. Operational challenges, including rising expenses and digital rollout issues, may offset profit margin gains and hinder future clinic and revenue growth.
View narrative
US$4.00
FV
0.3% overvalued
intrinsic discount
9.38%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
5 days ago
author updated this narrative
biote
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Sales Force Expansion Will Drive Clinic Onboarding Amid Competitive Concerns
Key Takeaways Sales force expansion, tech upgrades, and vertical integration are expected to boost clinic growth, margins, and long-term revenue sustainability. Growth in dietary supplements and digital channels diversifies earnings and provides greater resilience and recurring profitability.
View narrative
US$9.65
FV
58.4% undervalued
intrinsic discount
10.04%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
5 days ago
author updated this narrative
biote
AN
AnalystHighTarget
Consensus Narrative from 5 Analysts
Aging Population And Personalized Medicine Will Expand Global Care Networks
Key Takeaways Expanding sales force, new clinics, and software adoption are set to accelerate nationwide growth, improve patient retention, and boost recurring revenues and profitability. Vertical integration and dietary supplement momentum drive better margins, operating leverage, and increased share of consumer health and wellness spending.
View narrative
US$8.00
FV
49.9% undervalued
intrinsic discount
11.39%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
8 days ago
author updated this narrative
Your Valuation for
BTMD
BTMD
biote
Your Fair Value
US$
Current Price
US$4.01
44.2% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-8m
317m
2015
2018
2021
2024
2025
2027
2030
Revenue US$317.4m
Earnings US$33.5m
Advanced
Set Fair Value